


































Talking about human papillomavirus and cancer
Hendry, Margaret; Pasterfield, Diana; Gollins, Simon; Adams, Richard; Adams,
Mererid; Fiander, Alison; Robling, Michael; Campbell, Christine; Bekkers, Marie-
Jet ; Hiscock, Julia; Nafees, Sadia; Rose, Janice; Stanley, Margaret; Williams,





Publisher's PDF, also known as Version of record
Cyswllt i'r cyhoeddiad / Link to publication
Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Hendry, M., Pasterfield, D., Gollins, S., Adams, R., Adams, M., Fiander, A., Robling, M.,
Campbell, C., Bekkers, M-J., Hiscock, J., Nafees, S., Rose, J., Stanley, M., Williams, O., Mkain,
M., & Wilkinson, C. (2017). Talking about human papillomavirus and cancer: development of
consultation guides through lay and professional stakeholder coproduction using qualitative,
quantitative and secondary data. BMJ Open, 7(6), [e015413]. https://doi.org/10.1136/bmjopen-
2016-015413
Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or
other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal
requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private
study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to
the work immediately and investigate your claim.
 11. May. 2021
 1Hendry M, et al. BMJ Open 2017;7:e015413. doi:10.1136/bmjopen-2016-015413
Open Access 
Talking about human papillomavirus 
and cancer: development of consultation 
guides through lay and professional 
stakeholder coproduction using 
qualitative, quantitative and 
secondary data
Maggie Hendry,1 Diana Pasterfield,1 Simon Gollins,2 Richard Adams,3 
Mererid Evans,3 Alison Fiander,4 Michael Robling,5 Christine Campbell,6 
Marie-Jet Bekkers,5 Julia Hiscock,1 Sadia Nafees,1 Janice Rose,7 
Margaret Stanley,8 Olwen Williams,9 Matthew Makin,10 Clare Wilkinson1 
To cite: Hendry M, Pasterfield D, 
Gollins S, et al.  Talking 
about human papillomavirus 
and cancer: development 
of consultation guides 
through lay and professional 
stakeholder coproduction using 
qualitative, quantitative and 
secondary data. BMJ Open 
2017;7:e015413. doi:10.1136/
bmjopen-2016-015413
 ► Prepublication history and 
additional material are available. 
To view these files please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2016- 
015413).
Received 2 December 2016
Revised 11 April 2017
Accepted 27 April 2017
For numbered affiliations see 
end of article.
Correspondence to




Background High-risk human papillomaviruses 
(HPVs) cause all cervical cancer and the majority of 
vulvar, vaginal, anal, penile and oropharyngeal cancers. 
Although HPV is the most common sexually transmitted 
infection, public awareness of this is poor. In addition, 
many clinicians lack adequate knowledge or confidence 
to discuss sexual transmission and related sensitive 
issues. Complex science needs to be communicated in 
a clear, digestible, honest and salient way. Therefore, the 
aim of this study was to coproduce with patients who 
have cancer appropriate resources to guide these highly 
sensitive and difficult consultations.
Methods A matrix of evidence developed from a variety 
of sources, including a systematic review and telephone 
interviews with clinicians, supported the production of 
a draft list of approximately 100 potential educational 
messages. These were refined in face-to-face patient 
interviews using card-sorting techniques, and tested 
in cognitive debrief interviews to produce a â€˜fast and 
frugalâ€™ knowledge tool.
Results We developed three versions of a consultation 
guide, each comprising a clinician guidance sheet and 
patient information leaflet for gynaecological (cervical, 
vaginal, vulvar), anal or oropharyngeal cancers. That 
cancer could be caused by a sexually transmitted virus 
acquired many years previously was surprising to many 
and shocking to a few patients. However, they found 
the information clear, helpful and reassuring. Clinicians 
acknowledged a lack of confidence in explaining HPV, 
welcomed the clinician guidance sheets and considered 
printed information for patients particularly useful.
Conclusion Because of the â€˜shock factorâ€™, 
clinicians will need to approach the discussion of 
HPV with sensitivity and take individual needs and 
preferences into account, but we provide a novel, 
rigorously developed and tested resource which should 
have broad applicability in the UK National Health 
Service and other health systems.
InTroducTIon
Nearly all men and women are exposed 
to human papillomavirus (HPV) at some 
stage in their lives. Persistent infection 
with high-risk HPV types causes virtually all 
cervical cancer,1 most vulvar, vaginal2 and 
anal cancers,3 approximately half of penile 
cancers4 and over half of oropharyngeal 
(tonsil, base of tongue) cancers. In some 
instances, HPV status will determine the 
approach to cancer treatment.5 It also has 
a profound effect on prognosis in patients 
with oropharyngeal cancer.6 Health profes-
sionals must be prepared to discuss HPV 
status because affected patients may want to 
know the cause of their condition and may 
question the implications for their sexual 
Strengths and limitations of this study
 ► We provide a rigorously developed and tested 
resource comprising a brief and succinct guidance 
sheet to help doctors address their patients’ human 
papillomavirus (HPV) information needs and a more 
detailed information sheet for patients to take home.
 ► This resource has been produced in partnership with 
patients and clinicians to provide information they 
wanted in a way that they found honest, accurate, 
reassuring and useful.
 ► Due to its comparative rarity, we did not include 
patients with HPV-related penile cancer; therefore, 
we have no direct evidence that this resource would 
be equally suitable for these patients.
 ► We have only limited evidence of acceptability 
to patients across all sexual orientations and 
ethnicities.
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partners. Although discussions about HPV between 
patients and health professionals are becoming more 
common in cervical disease, patients express concern 
about the stigma attached to sexual transmission.7–9 
There is little rigorous research into how clinicians 
communicate with patients for other cancers associated 
with HPV.
Systematic reviews demonstrate consistently that 
women have poor knowledge of HPV and lack of aware-
ness that it is a sexually transmitted causative factor for 
cervical cancer.10 11 Furthermore, women who are found 
to be HPV positive during cervical screening experience 
considerable distress and anxiety largely due to their lack 
of understanding of the commonness of HPV, and their 
tendency to view it in terms of other sexually transmitted 
infections (with associated stigma) or confuse it with HIV.11 
Healthcare professionals often have difficulty initiating 
discussions about sexual matters with patients, and find 
it challenging to explain HPV infection; they describe it 
as a ‘can of worms’.12 To address stigma and psychosexual 
information needs, in addition to explaining the nature 
of HPV infection and the link between HPV and cancer, 
there is a clear need for new ‘fast and frugal’ knowledge 
tools for such sensitive, complex clinical consultations.13
A patient-centred approach has been proposed, but 
there is a lack of studies where patient input has informed 
education and counselling strategies.14 Written material, 
designed to inform and educate both healthcare profes-
sionals and patients, and thus improve health outcomes, 
has been used effectively to deliver patient-sensitive, 
evidence-based information about difficult scientific 
subjects.15 We intentionally included patient perspectives 
in a strategy designed to provide timely and accurate 
information on the role of HPV infection in cancer. 
Our methodological approach fitted with the Cochrane 
Consumers and Communication Review Group’s ‘The 
Knowledgeable Patient’,16 a summary of health benefits 
from improving patient and public/professional inter-
actions by integrating systematic review evidence with 
patient and public views, as well as the co-production 
principle embedded in National Health Service Wales’ 
‘Prudent Healthcare’.17 We also drew on the resources 
and recommendations for producing high-quality 
patient information outlined by the Patient Information 
Forum.18 19
Although there is quite a lot of publicly available 
information about HPV and cervical cancer, much of it 
focuses on cancer prevention (ie, HPV vaccination and 
HPV testing within cervical screening programmes), 
and there is much less information available about other 
cancer sites. Furthermore, while much of the relevant 
information is transferable across the cancers, some of it 
relates only to one cancer site. We aimed to develop and 
field-test evidence-based cancer site-specific versions of 
an HPV consultation guide, including ‘take-home’ infor-
mation for patients diagnosed with HPV-related cancer. 
These guides were to contain the most salient points not 
to miss, rather than verbatim wording for a consultation, 
and were designed to reduce anxiety and increase knowl-
edge about HPV in patients with specific cancers.
MeThods
The methods for this study are described in detail in a 
protocol paper published during the data collection 
period20 and a schematic overview is presented in figure 1. 
In brief, consultation guides were developed in two stages 
and tested in a third.
First, a list of approximately 100 draft messages 
was generated based on a synthesis of findings from 
previous published and unpublished work relating 
to cervical cancer.21–23 This list was augmented by 
additional messages nominated by the study advisory 
group or resulting from targeted literature searches to 
address the remaining relevant cancers, a systematic 
review of information-based interventions for patients 
with HPV-related cancers, and telephone interviews 
with cancer clinicians. Data extracted from each of 
these sources were aggregated in a matrix of evidence 
(see online supplementary file 1) to support the draft 
messages. After a review of the evidence matrix by our 
study advisory group including specialists in each type of 
HPV-related cancer, HPV pathology and sexual health, 
the messages were either accepted verbatim, accepted 
with modifications or considered not sufficiently rele-
vant or lacking in evidence, and deselected. Thus, a 
revised list of 32 provisional messages was developed. 
Since some messages were relevant only to specific 
cancers, three versions of the list were created to be 
appropriate for patients with gynaecological (cervical, 
vulvar, vaginal), anal or oropharyngeal cancers.
Stage 2 involved two phases of face-to-face exploratory 
interviews with patients diagnosed with gynaecological, 
anal or oropharyngeal cancers (penile cancer was not 
included because of the rarity of this disease and the 
difficulty in identifying suitable patients). In phase 1, the 
provisional messages were presented to participants in 
the format of statements printed on cards, and we drew 
on methods used in website design to sort and priori-
tise content.24–26 In phase 2, participants commented on 
the clarity of the selected messages, including specifics 
such as the tone and language used. Data comprising 
comments and suggestions from both phases were aggre-
gated, summarised and reviewed, and the messages were 
modified accordingly. The research team structured the 
modified messages in a format consisting of one page of 
narrative information and one page of ‘frequently asked 
questions’ with answers to comprise three cancer-specific 
versions of the patient leaflet element of the consultation 
guide. These were reviewed by the study advisory group, 
chiefly to ensure the scientific accuracy of the information, 
revised and recirculated until final versions were agreed. 
Text from these versions was selected and formatted to 
provide the one-page clinician guidance element of the 
consultation guide. Thus, three cancer-specific versions 
of a consultation guide, each comprising a clinician 
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guidance sheet and a patient information leaflet, were 
produced.
In stage 3, we adapted cognitive interviewing methods, 
using probing and ‘think aloud’ techniques to assess 
participants’ understanding of the patient leaflets.27 28 We 
also explored their views, reactions and feelings about 
the information they had received, for example, how they 
would use the information, whether they would share it 
and whether it made them feel differently about them-
selves. As additions to the protocol, we circulated the 
clinician guidance sheets by email to the clinicians who 
had participated in telephone interviews and asked them 
for feedback on their usefulness to patients and them-
selves. Finally, we presented our methods and findings 
to a group of cancer patients and carers from the North 
Wales Cancer Patient Forum and invited comments and 
discussion.
The study was granted UK NHS ethical approval. 
All patients recruited into the study were initially 
approached in private by the cancer clinician treating 
them during a consultation. They were given a verbal 
explanation of the study and supplied with a written 
information sheet and reply slip to take home. On 
receipt of the completed reply slip, they were contacted 
by a member of the research team to arrange an inter-
view, which could be conducted in a private room in 
the university or hospital or in the participant’s own 
home, according to their preference. The interviewer 
sought confirmation that the participant had read and 
understood the information, and responded to any 
further questions, before obtaining written consent and 
commencing the interview.
FIndIngs
stage 1 findings: developing the provisional messages
Relevant findings from an earlier study conducted by 
members of this team, including published and unpub-
lished work on HPV and cervical cancer prevention, were 
used to populate a matrix of evidence to support the draft 
messages as described in the methods section.21–23 Four 
studies were included in a new systematic review of infor-
mation-based interventions for patients with HPV-related 
cancers. One qualitative study29 and one survey30 both 
investigated the informational and psychosocial needs 
of patients with oropharyngeal cancer. One study used 
audio-recorded data and a brief questionnaire to examine 
the content and quality of postcolposcopy consultations.31 
Finally, one study used an intervention comprising a fact 
sheet developed from a review of available pamphlets, 
combined with a 40 min consultation with a nurse prac-
titioner colposcopist, and compared compliance to 
postcolposcopy recommendations with a control group 
who did not receive the intervention.32 The review is fully 
Figure 1 Overview of study methods. 
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reported in online supplementary file 2. Data from the 
included studies were added to the evidence matrix to 
inform message development. A number of additional 
articles were identified from targeted literature searches 
or by members of the study advisory group to fill evidence 
gaps in the matrix.
We attempted to identify and contact all the cancer 
clinicians working in Wales with the aim of interviewing 
a purposive sample of ~40 working across Wales and 
in varied clinical roles. Thirty-six clinicians, including 
oncologists, surgeons, clinical nurse specialists, colpos-
copists and speech and language therapists, took part in 
telephone interviews, which were audio-recorded. Data 
from the transcriptions were summarised and, together 
with illustrative quotations, entered into the matrix of 
evidence (see online supplementary file 1). While a 
few clinicians said that their patients never asked about 
HPV and so discussions never arose, this perception may 
have been related to their specific clinical role, that is, 
if patient encounters were confined to a point when the 
focus was on treatment and prognosis. Some indicated 
that they did not mention HPV to the patients because 
they considered it to be not relevant to disease manage-
ment or not their role. However, many clinicians said that 
patients were becoming more aware of HPV, that some 
were doing their own research on the internet and that 
most asked what caused their cancer.
A minority of clinicians were completely comfortable 
with giving frank and open explanations (including 
the role of oral/anal sex in transmission, if applicable), 
clearly exercised tact and sensitivity and were conscious of 
the potential for partner problems and the possible need 
for privacy. They emphasised the normality and common-
ness of HPV infection, and were inclusive, using the word 
‘we’, as in ‘we all get it’. They allayed concerns about fault 
and blame and made an effort not to be judgemental. 
However, many freely admitted to a lack of confidence in 
their own knowledge/ability to explain HPV to patients. 
A few commented about the need for training and the 
lack of available patient information. Several clearly 
found talking about sexual transmission embarrassing 
and confessed to being ‘out of their comfort zone’. 
Conversations about HPV were described as ‘awkward’, 
‘a can of worms’ and ‘a minefield’. There was evidence 
of a degree of age and gender bias, with a perception 
that older patients were less likely to be interested in 
discussing HPV and more likely to be embarrassed, and 
that women were more likely to want to talk about it than 
men. Common ways of managing these difficulties were 
to give limited information and assume that if patients 
did not ask questions, they understood and were ‘OK with 
it’, or to allow the conversation to be ‘patient-led’, that 
is, not to mention HPV at all unless the patient raised it 
first. Some explained HPV as a virus but did not mention 
its mode of transmission, or referred to it obliquely, for 
example, ‘only women who have been sexually active get 
this’ or ‘it comes from a woman’s cervix’. Three inter-
viewees reported having observed patients being upset 
by insensitively handled discussions, but there were also 
reports of patients being extremely relieved when their 
fears about infidelity or having ‘given their partner 
cancer’ were allayed.
After advisory group review and discussion of the 
completed evidence matrix, eight messages were dese-
lected, leaving a list of 24 provisional messages comprising 
15 generic messages, four applicable to oropharyngeal 
cancers, three to anal cancers and two to gynaecolog-
ical cancers. Each message was underpinned by at least 
two different types of evidence and was considered by 
the advisory group to be useful and appropriate. Table 1 
gives the list of messages and evidence sources; table 2 
comprises an extract from the draft message evidence 
matrix (see online supplementary file 1) illustrating how 
each message was developed.
stage 2 findings: refining the provisional messages and 
developing the consultation guides
Characteristics of the participants in all stages of this study 
are described in table 3. In all, 59 people took part in face-
to-face interviews to refine the provisional messages—30 
in phase 1 interviews to prioritise and comment on the 
content of the messages and 29 in phase 2 interviews 
to comment on the language and tone of the messages 
and eliminate repetition. Most people knew very little 
about HPV, indeed many had never heard of it before 
being recruited to the study; a few confused it with HIV. 
Therefore, they were somewhat taken aback at the infor-
mation that a virus could cause cancer, and that HPV is 
so common and easily passed on. Many were surprised, 
and a small minority quite shocked, to find that that their 
cancer might have been caused by a sexually transmitted 
infection, and especially that it could have been acquired 
many years ago, although for some this was a relief as it 
exonerated their current partner.
While most participants took this new information 
in their stride, several struggled to varying degrees with 
feelings of guilt and worry. A particular concern for a 
few was that they felt ‘dirty’, and two asked whether the 
transmission of HPV was associated with poor personal 
hygiene. Some felt stigmatised by having an infection that 
was sexually transmitted, even though they had had a very 
limited number of sexual partners. One woman asserted 
that ‘older people’ should not be told that HPV is sexually 
transmitted, ‘This is the most devastating thing for our age 
group’. Patients with anal cancer were especially likely to 
be embarrassed, but were reassured to have information 
that explained how HPV could be transmitted by intimate 
contact but not necessarily anal sex. To a lesser extent, 
patients with oropharyngeal cancer had similar concerns 
that people would assume they had engaged in oral sex. 
Indeed, these concerns proved to be well-founded in some 
instances by health professionals or acquaintances making 
comments to that effect. Nevertheless, the majority felt 
that ‘people should know’, and were reassured that ‘it was 
not their fault’. Questions that commonly arose and were 
not addressed by any of the messages were whether they 
group.bmj.com on September 13, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
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were at risk of a further HPV-related cancer at a different 
site or whether their partner was at risk.
In phase 1, participants each selected five messages that 
were most important to them.The results of this priori-
tisation exercise are included in a summary analysis of 
the phase 1 and 2 interviews. This is provided in full in 
online supplementary file 3, of which an extract appears 
in table 4. There was a degree of consensus among the 
participants that pointed to a split into a high-scoring 
group of messages, which ≥15 out of 30 rated in their top 
5, and a low-scoring group which ≤8 out of 30 rated in 
their top 5. Every message was rated in the top 5 at least 
twice, and many participants said that all the messages 
were important. Messages in the high-scoring group were 
related to the prevalence and natural history of HPV 
and cancer. Although participants often asked questions 
about the effects of HPV and cancer, particularly in terms 
of their possible impact on relationships, these messages 
were in the lower-scoring group.
Several participants pointed out repetition and overlap 
between the messages and that, as a consequence, sexual 
transmission was overemphasised, ‘another one about 
sex!’. Therefore, in phase 2, the cards were grouped 
in topic areas rather than presented one at a time, and 
participants considered how to eliminate repetition and 
whether, and how, to merge overlapping messages, as 
well as commenting on the content, language and tone. 
Suggestions for changes were noted (verbatim if specific 
rewording was suggested). Data relating to each message, 
from both phases of interviews, were summarised with 
relevant illustrative quotes. After review and discussion, 
the messages were rephrased to improve conciseness, 
comprehensibility and readability, and merged where 
necessary to eliminate repetition and overlap. The final 
list of messages for each cancer type, described in table 5, 
was reviewed by the advisory group.
While retaining the newly developed phrasing of each 
of the resulting 10 generic and nine cancer-specific 
Table 2 Extract from the draft message evidence matrix
Draft messages
Developed 
in HPV Core 
Messages 
Study (marked 
























from reviews of 






Identified in the 
‘Talking about 
HPV’ systematic 
review or by 
members of the 
expert group
Telephone interviews with 
healthcare professionals







HPV is very 
common; most 
sexually active 
people will have 
it at some point 
in their life.*
Most women 
in the NHS 
cervical screening 
programme HPV 
pilot sites who were 
interviewed said they 
had been unaware 
of HPV prior to their 
results letter.
Only 9.2% of the 




the statement, ‘Most 
people will get an 
HPV infection during 
their life’ was true.
6.1% of the 




infection to be rare.
The prevalence 
of HPV in the 
USA ranged from 










Few knew HPV is 
highly prevalent.22
Nearly three out 
of four people 
between the ages 
of 15 and 49 have 
been infected 
with HPV at some 
point in their 
lives.32
Most of us will 
acquire an HPV 
infection at some 
point in our lives, 
usually without 
knowing about it. 
Telling patients 
this, and being 
inclusive, will help 
them feel that 
HPV is ‘normal’.41
Most sexually 
active people will 
get HPV early in 
their lifetimes.14
Clinicians explain to patients 
that HPV infection is very 
common and can take years 
to develop, but often seek to 
avoid emphasising the sexually 
transmitted nature of the virus.
‘It is as common as having a 
cold.’
‘I explain that the virus is like 
the influenza virus in terms of it 
is a virus and that pretty much 
all of us can get it…I hardly 
ever say that it is sexually 
transmitted unless they bring 
that up.’
‘We try and say to them it is a 
virus that’s sexually transmitted 
but not in a way to make them 
feel they have done something 
wrong.’
‘I tell them sex is a healthy 
thing and that most of us are 
carrying it (HPV) so they don’t 
feel dirty.’







at some point 
in their life.
HPV, human papillomavirus.
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messages, they were organised into three versions of a 
new ‘consultation guide’ format. For each type of cancer 
(gynaecological, anal, oropharyngeal), a one-page clini-
cian guidance sheet and a two-page patient information 
leaflet were created. To enhance comprehension and 
readability, we framed page 1 of the patient information 
leaflet (comprising the high-scoring messages) as a narra-
tive and page 2 (comprising the lower-scoring messages) 
as ‘frequently asked questions’ with answers. For the 
clinician guidance sheet, we also selected a question and 
answer format: If your patient asks…, try saying…. as we 
considered this to be a more helpful, less directive format 
that might be more acceptable to clinicians.
stage 3 findings: testing the consultation guides
Cognitive debrief interviews
Another 17 people with HPV-related cancers, recruited 
as before, took part in face-to-face cognitive debrief inter-
views. To assess comprehension, participants were asked 
to reflect back the meaning of the messages to the inter-
viewer (‘what does this mean to you?), as well as what they 
thought about each message and how it made them feel. 
The majority of participants reported that they under-
stood the content of the information sheet and found 
it informative, reassuring and interesting, and there 
was overall agreement on the comprehensibility, clarity 
and completeness of all the messages, ‘the message it’s 
intended to deliver has been delivered to me’. Therefore, 
although cognitive debrief interviews are often used to 
fine-tune wording, no further modifications were needed. 
As before, there was a degree of surprise or even shock; 
however, for most participants, being helped to under-
stand that HPV was a common infection, was not their 
fault and they could not have prevented it was reassuring, 
‘I might think about it more later, but I shan’t worry 
about it’.
Four of the participants who had been told about 
HPV outside the study context reported particularly 
upsetting experiences. They variously described: being 
referred to a sexual health clinic, being made to feel 
‘dirty’ and ‘like a prostitute’, doctors insisting on HIV 
and chlamydia testing, being told that HPV infection 
was a result of ‘being unclean and having a lot of anal 
sex’ or simply not being looked at when the explanation 
was being given. In contrast, they found the information 
sheet reassuring, ‘It’s a shame the doctors didn’t speak 
to me like that’. Some participants felt that information 
should be more widely available. They reported that 
having an HPV-related cancer, as opposed to, say, breast 
cancer or bowel cancer, which are more commonly 
known and spoken about, could be very isolating. Some 
did not speak to anyone about their cancer, not just 
because they felt a degree of shame and stigma associ-
ated with it, but also because they did not know how to 
explain it and did not think others would understand; 
Table 3 study participant characteristics
Cancer patients n=76
Cancer type Gynaecological (n=25) Oropharyngeal(n=23) Anal (n=28) Total (n=76)
Age: median and range 58 (20–76) 61 (36–85) 60.5 (38–80) —
Gender 18 male 8 male 26 male
25 female 5 female 20 female 50 female
Health literacy*
1 (never need help) 23 16 24 63
2 0 5 1 6
3 1 0 2 3
4 0 1 1 2
5 (always need help) 1 1 0 2
North Wales 13 20 16 49
South Wales 12 3 12 27
Cancer clinicians n=36
  Role Gynaecological Oropharyngeal Anal Multisite/other
  Surgeon/physician 5 4 1 3
  Oncologist 4 1 3 2
  Specialist nurse 3 6 1 0











*How often do you need to have someone help you when you read instructions, pamphlets or other written material from your doctor or 
pharmacy? (1—never, 2—rarely, 3—sometimes, 4—often, 5—always)
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the information gave them the ability to talk: ‘knowl-
edge is power’ said one.
There was no overall consensus on how information 
about HPV should be given to patients, that is, by whom, 
at what time point and in what circumstances. Some 
people thought nurses were best placed as they had more 
time and ‘might be more sensitive’; others thought it 
was a doctor’s responsibility ‘because they know more’. 
While some people wanted to have been told about HPV 
right from the beginning, many thought it was too much 
information to absorb at the time of diagnosis and would 
get lost among the plethora of information given at that 
time. Among those who tended to go accompanied to 
consultations, some thought it would be embarrassing to 
have a partner present, or were concerned about what 
they might think; others considered it ‘a journey you go 
through together’.
Most participants found the information useful and 
acceptable and although a small minority of partici-
pants were shocked by some of the content, all expressed 
approval of the manner in which the information was 
presented. They wanted information that was ‘straight-
forward and easy to understand’. Addressing repetition 
in the provisional messages meant that there was less 
emphasis on sexual transmission, with a result that the 
final versions appeared to be more reassuring. A summary 
of the stage 3 interview findings is available in online 
supplementary file 4.
Feedback from cancer clinicians on the clinician guidance sheets
Of the 36 clinicians who took part in telephone inter-
views in stage 1 of the study, 17 responded to an email 
request for feedback. We sent them the appropriate 
cancer-specific version of the clinician guidance sheet 
and asked them, on a scale of 1 to 5, how useful it was, 
how likely they were to use it in consultations and why. A 
few of the respondents commented but did not score the 
guidance sheets; 8 out of 12 who did gave a score of 4 or 
5 for usefulness and 8 out of 13 gave a score of 4 or 5 for 
likelihood that they would use it. Those who scored the 
items lower than 4 gave one of two reasons: either that it 
was already part of their routine practice to talk to their 
patients about HPV , or that  they would only give infor-
mation to patients who asked about HPV,  which rarely 
happened in their experience. Other comments were 
very positive; ‘useful’, ‘relevant’, ‘simple to understand’ 
and so on. Six respondents specifically mentioned that it 
would be particularly useful to have a written handout to 
give to patients, one thought the guidance sheet would 
be useful as a teaching aid and another commented 
Table 4 Extract from the summary analysis of phase 1 and 2 interviews
Messages



















people will be 
exposed to at 






message in their 
top 5
Many patients agreed that this 
was a reassuring statement and 
that they were not to blame: ‘It’s 
just unfortunate, like all illnesses.’ 
However, they felt that people 
should be more aware, and one 
patient found it alarming to read. 
Another suggested merging it with 
message 6.
‘Quite reassuring… you’re not like 
a leper or something… you don’t 
want to think it was your fault’
‘Most, that could be everybody…. 
it's important because I thought, 
Jesus, everyone has got it then, 
probably and when I first saw this I 
thought: what have I done?’
‘If you lead a normal life you have a 
high chance of HPV’
‘This puts it into perspective, it is 
common, it doesn’t always end up 
causing cancer.’
‘I didn’t realise that most people 
carry the virus. It is important to tell 
my children and my friends about 
this; everyone should know this—it 
makes you more aware.’
Most patients commented 
that this is a very useful 
statement but not many 
offered suggestions for 
rewording. One patient 
commented that it gives 
the impression that it only 
concerns people who 
are sexually active now; 
it doesn’t indicate that it 
is relevant to people who 
were sexually active in the 
past. One questioned the 
wording ‘exposed to’ and 
whether it meant you had 
been at risk of catching 
it and you didn’t or that 
you did. One wondered 
if something like a mind 
map would be useful, 
where the key point was 
central and other points 
in boxes leading off. One 
suggested combining 
with message 6, ‘you 
get HPV from having sex 
or intimate contact with 
another person’.
HPV should be written 
out, otherwise easy to 
confuse with HIV:
Human papillomavirus 
(HPV) is a very common 
virus…
HPV is a very common 
virus that most sexually 
active people will be 
exposed to and acquire 
at some point in their 
life.
… that most people 
who are or have been 
sexually active will have 
been exposed to…
HPV is a very common 
virus that most 
(how many? add 
percentages) sexually 
active people will be 
exposed to at some 
point in their life, no 
matter what your age. 
You don't know how 
long in the future it will 
be before it shows, if 
at all.
HPV is a virus that 
is passed during 
sex or intimate 
contact. It affects 
both men and 
women, and it is so 
common that most 
of us get it at some 
point in our lives.
Combining 
messages 1, 2 and 
6 to simplify and 
address comments 
about repetition.
The heading of 
the final version 
will have human 
papillomavirus 
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that a useful addition would be signposting to further 
resources.
Discussion with North Wales Cancer Patient Forum
Five cancer patients and carers from the North Wales 
Cancer Patient Forum met with the research team and 
we presented the study methods and findings. After a 
lengthy discussion, the group reaffirmed our findings, 
saying that the information was very helpful. They 
expressed interest in how the consultation guides could 
be put into practice, and felt that this type of infor-
mation should be disseminated more widely to raise 
awareness among the public.
dIscussIon
The product of this study is a suite of novel, coproduced 
consultation guides comprising clinician guidance sheets 
and patient information leaflets for HPV-related gynae-
cological, anal and oropharyngeal cancers. They were 
developed through a systematic process that included 
ensuring a robust evidence base and the scrutiny of 
experts at every stage. Crucially, they were coproduced 
and tested by cancer patients who, overall, found the 
resulting patient information leaflets to be interesting, 
accessible, informative and reassuring. In interviews, 
clinicians acknowledged a need for more education in 
the science relating to HPV and cancer and for training 
in communicating sensitive information to patients. 
Although slightly less than half of them responded to 
an email invitation to give feedback on the clinician 
guidance sheets, several mentioned a lack of patient infor-
mation about HPV and three of them had written their 
own patient information leaflets to fill this gap. Repre-
sentatives from the North Wales Cancer Patient Forum 
expressed enthusiastic support for the provision of infor-
mation in general to patients and the public, and deemed 
the information we provided to be interesting, relevant, 
clear and easy to understand. All three versions of the 
clinician guidance sheets and patient information leaf-
lets are available as supplementary files to download (see 
Table 5 Final list of messages incorporated in consultation guides
Generic messages Cancer site-specific messages
The facts about HPV and cancer
HPV is a virus that is passed from one person to another during sex or physical 
intimacy. It affects both men and women, and it is so common that most of us 
get it at some point in our lives.
HPV is usually cleared by the body’s own defences but, in a few people, it stays 
in the cells of the affected area for months or years. Then it sometimes causes 
the cells to change, and that may lead to cancer.
Even if HPV causes cells to change, it can take another 10 years or more for 
cancer to develop.
Most people never know they had HPV because there aren’t usually any 
symptoms. It is hard to know when you got HPV or who you got it from.
There is no treatment for HPV but there’s now a vaccination to prevent it. It’s best 
for young people to be vaccinated before they are sexually active.
Frequently asked questions
Q: What does this mean for my relationship?
A: Having HPV-related cancer doesn’t mean you or your current partner have had 
sex with someone else. The virus was likely picked up many years ago and there 
is no need for shame or blame.
You and your partner will have already shared whatever infections you have and 
no changes in physical intimacy are needed.
Q: Am I or my partner at risk of getting another HPV-related cancer?
A: You might be at a slightly higher risk, so you should report any symptoms to 
your doctor, but remember that these cancers are very rare.
Q: What about previous partners?
A: There is no need to tell previous partners you have HPV. There is no test or 
treatment for it; most people clear the virus without treatment and without even 
knowing they had it.
Q: Could I have done anything to prevent getting HPV?
A: No, it is so common that nearly all adults get it and condoms would not have 
given you complete protection.
However, if you are a smoker, giving up smoking may help your recovery from 
cancer.
Q: Could I have got HPV any other way?
A: This is very unlikely because HPV targets a type of cell found in the lining of 
parts of the body that only come into contact during sexual intimacy.
Gynaecological cancers
HPV causes all cervical cancer, nearly half 
of vulvar and two-thirds of vaginal cancers. 
It can also cause some cancers of the anus, 
penis and head and neck.
There is no treatment for HPV but there’s 
now a vaccination to prevent it. Girls are 
vaccinated in the first year of high school.
Anal cancer
HPV causes nearly all anal cancers. It also 
causes cervical cancer and some cancers 
of the vulva, vagina, penis and head and 
neck.
HPV can be spread to the anal area by 
intimate skin-to-skin contact or anal sex.
It is easy for HPV to be transferred between 
the genital and anal area, especially in 
women.
Head and neck cancersHPV causes about 
half of oropharyngeal cancers (which can 
involve the tonsils, tongue base and soft 
palate). It also causes cervical cancer and 
some cancers of the vulva, vagina, anus 
and penis.HPV can be transmitted by 
oral sex as well as other forms of intimate 
contact.HPV may be transmitted by deep 
or ‘French’ kissing but not by sharing drinks 
or kissing on the cheek.Head and neck 
cancers caused by HPV usually respond 
well to treatment.
HPV, human papillomavirus.
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online supplementary files 5–10), and may be used under 
the terms of the Creative Commons Attribution License, 
which permits use, distribution and reproduction in any 
medium, provided the original work is properly cited.
This was a mixed-methods study in which we creatively 
developed messages through an iterative process of lay 
and professional stakeholder coproduction using both 
primary qualitative, quantitative and secondary data 
collection and analysis methods. We took a pragmatic, iter-
ative approach, borrowing and adapting techniques from 
a variety of sources and we used these methods together 
in a systematic and transparent manner, according to 
a peer-reviewed, published protocol.20 We recruited 
male and female participants with a range of ages and 
spread across the cancer sites. We aimed for a sample 
with a range of socio-economic backgrounds by means of 
recruiting from diverse geographical areas across North 
and South Wales, and a range of understanding based 
on a health literacy question, ‘How often do you need 
to have someone help you when you read instructions, 
pamphlets, or other written material from your doctor 
or pharmacy?’33; however, our sample was not ethnically 
diverse. Therefore, we can only make limited comments 
about the usefulness or acceptability of the consulta-
tion guides among minority populations. One woman 
was extremely shocked by the information because the 
discussion of any matters relating to sex was taboo in 
her community. We did not ask participants about their 
sexual orientation, but one who volunteered that they 
were in a same-sex relationship said that our information 
was perfectly acceptable, ‘the offensive bit can come from 
doctors not knowing what to say…’
To our knowledge, this was the first study to develop 
educational resources for both clinicians and patients, 
for three types of HPV-related cancers, that were both 
evidence-based and coproduced by patients. Several 
authors have documented the need for patients to be 
informed and counselled about HPV,29 34 35 and that 
physicians lack the ability to do so for want of adequate 
knowledge34 36 or because of discomfort in talking about 
sexual matters.37 Some have identified questions that 
patients might ask and offered suggestions for explana-
tions that might be given.14 34 38 We drew heavily on the 
work of these and other authors to build the evidence base 
for our draft messages. However, the available literature 
was overwhelmingly related to cervical or oropharyngeal 
cancers only and patients were not directly engaged in 
the production of educational resources.
We did not attempt to recruit patients with penile 
cancer because this is a relatively rare condition; 
however, there is no obvious reason why an appropri-
ately modified version of the consultation guide would 
not be acceptable to them. The opinions of participants 
were divided with respect to the appropriate timing of 
introducing information about HPV, and whether it 
should be given privately or in the presence of a spouse 
or other companion. Although we provide a resource 
that will help clinicians to navigate these difficult 
consultations, they will still need to approach the discus-
sion of HPV with sensitivity and take individual needs 
and preferences into account.
These materials have the potential for wide dissemi-
nation and reach as the content has high provenance 
and is likely to be widely acceptable in the UK and other 
English-speaking countries. Potential formats include 
written or computerised prompts and web-based patient 
or clinician resources. Further research should consider 
which methods are most likely to ensure successful imple-
mentation and the degree to which the messages serve 
the needs of patient populations more diverse than those 
who contributed to the current version. As scientific 
understanding progresses, there will also be a need to 
review the validity of the messages and determine whether 
updates will be required.
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